Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19897341 | 0.86 | FFAR1 (0.32) | — | |
| SCHEMBL19897270 | 0.86 | FFAR1 (0.32) | — | |
| SCHEMBL7447678 | 0.86 | FFAR1 (0.32) | — | |
| SCHEMBL7447686 | 0.86 | FFAR1 (0.32) | — | |
| SCHEMBL19198820 | 0.84 | MMP2 (0.36) | MMP2ANPEP | |
| SCHEMBL14155394 | 0.81 | MMP2 (0.34) | MMP2ANPEPATM | |
| SCHEMBL15632175 | 0.79 | NR1H2 (0.40) | — | |
| SCHEMBL8262943 | 0.79 | NR1H2 (0.40) | — | |
| SCHEMBL16857486 | 0.79 | NR1H2 (0.40) | — | |
| SCHEMBL30680499 | 0.79 | NR1H2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| EP-2867238-B1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-08-09 | — | — | EP | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | MMP2 498/4885ANPEP 6/4885ATM 3744/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | MMP2 498/4885ANPEP 6/4885ATM 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.